{"id":692341,"date":"2022-10-05T08:08:19","date_gmt":"2022-10-05T12:08:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/"},"modified":"2022-10-05T08:08:19","modified_gmt":"2022-10-05T12:08:19","slug":"genenta-to-present-at-upcoming-scientific-and-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/","title":{"rendered":"Genenta to Present at Upcoming Scientific and Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MILAN, Italy and NEW YORK, Oct.  05, 2022  (GLOBE NEWSWIRE) &#8212; Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company\u00a0developing a\u00a0cell-based platform\u00a0harnessing the power of hematopoietic stem cells to provide durable and safe treatments for\u00a0solid tumors, will present at several upcoming scientific and investor conferences.<\/p>\n<p>\n        <strong>Roth Inaugural Healthcare Opportunities,\u00a0October 6, New York, NY<\/strong><br \/>\n        <br \/>Presenters: CEO\u00a0Pierluigi Paracchi, CMO\u00a0Carlo Russo<br \/>Time:\u00a0October 6, 10:15 AM ET<\/p>\n<p>\n        <strong>European Society of Gene &amp; Cell Therapy 29th Congress,\u00a0October 11-14,\u00a0Edinburgh, UK and virtual\u00a0<\/strong><br \/>\n        <br \/>Title: Genetically-modified hematopoietic stem cells as a one-time, systemic treatment for non-hematologic disorders<br \/>Type: Oral<br \/>Presenter: Bernhard Gentner,\u00a0SR-TIGET, Milan and Co-founder of Genenta<br \/>Time:\u00a0October 12,\u00a011:10 AM -1:15 PM BST<\/p>\n<p>\n        <strong>Society for Immunotherapy of Cancer 37th Annual Meeting, November 8-12, Boston, MA and virtual<\/strong><br \/>\n        <br \/>Title: Autologous macrophage-based immunotherapy Induces a pro-inflammatory state in GBM tumor microenvironment &#8211; (TEM-GBM)<br \/>Type: Poster<br \/>Presenter: CMO Carlo Russo<br \/>Time: November 10-11, 9:00 AM \u2013 8:30 PM ET<\/p>\n<p align=\"justify\">\n        <strong>About Genenta Science <\/strong>\n      <\/p>\n<p align=\"justify\">Genenta (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sxJfak3DUm8VfdJnRp2IZrnBpclNwSQUtJYm3GZ5d4BMEKHN0EIpiwmowuBkZbybzInwJjRFdF1bRPA7W-UsqbjYQopUj6iI30SmIdWOAOlWIzL5DYStC_0f9oZd37g9V820fruy0a0NYfqba9QuaKj3rpve8-A71uhxp4FnLrvQHXc7BBSIXGn-V0oGmMz10uftKSb7nsLz-NSoyqMM0DIwWbzpwF3mzAOfy6i85_A=\" rel=\"nofollow noopener\" target=\"_blank\">www.genenta.com<\/a>) is a clinical stage immune-oncology company\u00a0developing a\u00a0cell-based platform\u00a0harnessing the power of hematopoietic stem cells to provide durable and safe treatments for\u00a0solid tumors. Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro-environment. Genenta\u2019s lead product candidate,\u00a0Temferon, precisely targets the delivery of interferon-alpha to the tumor micro-environment,\u00a0minimizing systemic toxicity\u00a0while breaking tumor-induced immune tolerance. Our treatments are designed as\u00a0one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release contain \u201cforward-looking statements,\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d &#8220;will,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of the phase 1\/2a clinical trial or any studies relating to the treatment of glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM). Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Genenta Science S.p.A. (GNTA) undertakes no duty to update such information except as required under applicable law.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;text-align: left;vertical-align: middle;vertical-align: top\">Investor Relations &#8211; LifeSci Advisors<\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;text-align: left;vertical-align: middle;vertical-align: top\">Genenta Media<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Mary-Ann Chang, CFA<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Tiziana Pollio<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">+44 7483 28 48 53<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">+39 3482315143<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:mchang@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">mchang@lifesciadvisors.com<\/a>\n          <\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:tiziana.pollio@genenta.com\" rel=\"nofollow noopener\" target=\"_blank\">tiziana.pollio@genenta.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzA5OTdlOGItYjM1MS00NjE3LTgzODYtZjkzYmE5N2EwZTNjLTUwMDA3NDY0OA==\/tiny\/Genenta-Science.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company\u00a0developing a\u00a0cell-based platform\u00a0harnessing the power of hematopoietic stem cells to provide durable and safe treatments for\u00a0solid tumors, will present at several upcoming scientific and investor conferences. Roth Inaugural Healthcare Opportunities,\u00a0October 6, New York, NY Presenters: CEO\u00a0Pierluigi Paracchi, CMO\u00a0Carlo RussoTime:\u00a0October 6, 10:15 AM ET European Society of Gene &amp; Cell Therapy 29th Congress,\u00a0October 11-14,\u00a0Edinburgh, UK and virtual\u00a0 Title: Genetically-modified hematopoietic stem cells as a one-time, systemic treatment for non-hematologic disordersType: OralPresenter: Bernhard Gentner,\u00a0SR-TIGET, Milan and Co-founder of GenentaTime:\u00a0October 12,\u00a011:10 AM -1:15 PM BST Society for Immunotherapy of Cancer 37th Annual Meeting, November 8-12, Boston, MA and virtual Title: Autologous macrophage-based immunotherapy Induces &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Genenta to Present at Upcoming Scientific and Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692341","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genenta to Present at Upcoming Scientific and Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genenta to Present at Upcoming Scientific and Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company\u00a0developing a\u00a0cell-based platform\u00a0harnessing the power of hematopoietic stem cells to provide durable and safe treatments for\u00a0solid tumors, will present at several upcoming scientific and investor conferences. Roth Inaugural Healthcare Opportunities,\u00a0October 6, New York, NY Presenters: CEO\u00a0Pierluigi Paracchi, CMO\u00a0Carlo RussoTime:\u00a0October 6, 10:15 AM ET European Society of Gene &amp; Cell Therapy 29th Congress,\u00a0October 11-14,\u00a0Edinburgh, UK and virtual\u00a0 Title: Genetically-modified hematopoietic stem cells as a one-time, systemic treatment for non-hematologic disordersType: OralPresenter: Bernhard Gentner,\u00a0SR-TIGET, Milan and Co-founder of GenentaTime:\u00a0October 12,\u00a011:10 AM -1:15 PM BST Society for Immunotherapy of Cancer 37th Annual Meeting, November 8-12, Boston, MA and virtual Title: Autologous macrophage-based immunotherapy Induces &hellip; Continue reading &quot;Genenta to Present at Upcoming Scientific and Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T12:08:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genenta to Present at Upcoming Scientific and Investor Conferences\",\"datePublished\":\"2022-10-05T12:08:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/\"},\"wordCount\":522,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/\",\"name\":\"Genenta to Present at Upcoming Scientific and Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==\",\"datePublished\":\"2022-10-05T12:08:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genenta to Present at Upcoming Scientific and Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genenta to Present at Upcoming Scientific and Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Genenta to Present at Upcoming Scientific and Investor Conferences - Market Newsdesk","og_description":"MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company\u00a0developing a\u00a0cell-based platform\u00a0harnessing the power of hematopoietic stem cells to provide durable and safe treatments for\u00a0solid tumors, will present at several upcoming scientific and investor conferences. Roth Inaugural Healthcare Opportunities,\u00a0October 6, New York, NY Presenters: CEO\u00a0Pierluigi Paracchi, CMO\u00a0Carlo RussoTime:\u00a0October 6, 10:15 AM ET European Society of Gene &amp; Cell Therapy 29th Congress,\u00a0October 11-14,\u00a0Edinburgh, UK and virtual\u00a0 Title: Genetically-modified hematopoietic stem cells as a one-time, systemic treatment for non-hematologic disordersType: OralPresenter: Bernhard Gentner,\u00a0SR-TIGET, Milan and Co-founder of GenentaTime:\u00a0October 12,\u00a011:10 AM -1:15 PM BST Society for Immunotherapy of Cancer 37th Annual Meeting, November 8-12, Boston, MA and virtual Title: Autologous macrophage-based immunotherapy Induces &hellip; Continue reading \"Genenta to Present at Upcoming Scientific and Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T12:08:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genenta to Present at Upcoming Scientific and Investor Conferences","datePublished":"2022-10-05T12:08:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/"},"wordCount":522,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/","name":"Genenta to Present at Upcoming Scientific and Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==","datePublished":"2022-10-05T12:08:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODkyMCM1MTg0MDM2IzUwMDA3NDY0OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-present-at-upcoming-scientific-and-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genenta to Present at Upcoming Scientific and Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692341"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692341\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}